JP2009509535A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509535A5
JP2009509535A5 JP2008533574A JP2008533574A JP2009509535A5 JP 2009509535 A5 JP2009509535 A5 JP 2009509535A5 JP 2008533574 A JP2008533574 A JP 2008533574A JP 2008533574 A JP2008533574 A JP 2008533574A JP 2009509535 A5 JP2009509535 A5 JP 2009509535A5
Authority
JP
Japan
Prior art keywords
cysteine
scaffold
protein
natural
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008533574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/037713 external-priority patent/WO2007038619A2/en
Publication of JP2009509535A publication Critical patent/JP2009509535A/ja
Publication of JP2009509535A5 publication Critical patent/JP2009509535A5/ja
Withdrawn legal-status Critical Current

Links

JP2008533574A 2005-09-27 2006-09-27 タンパク様薬剤およびその使用 Withdrawn JP2009509535A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72127005P 2005-09-27 2005-09-27
US72118805P 2005-09-27 2005-09-27
US74362206P 2006-03-21 2006-03-21
PCT/US2006/037713 WO2007038619A2 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof

Publications (2)

Publication Number Publication Date
JP2009509535A JP2009509535A (ja) 2009-03-12
JP2009509535A5 true JP2009509535A5 (cg-RX-API-DMAC10.html) 2009-11-12

Family

ID=37900430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533574A Withdrawn JP2009509535A (ja) 2005-09-27 2006-09-27 タンパク様薬剤およびその使用

Country Status (7)

Country Link
US (2) US20070212703A1 (cg-RX-API-DMAC10.html)
EP (1) EP1929073A4 (cg-RX-API-DMAC10.html)
JP (1) JP2009509535A (cg-RX-API-DMAC10.html)
AU (1) AU2006294644A1 (cg-RX-API-DMAC10.html)
CA (1) CA2622441A1 (cg-RX-API-DMAC10.html)
SI (1) SI1996220T2 (cg-RX-API-DMAC10.html)
WO (1) WO2007038619A2 (cg-RX-API-DMAC10.html)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR673001A0 (en) * 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
US8299210B2 (en) * 2003-11-20 2012-10-30 Sanofi Pasteur Methods for purifying pertussis toxin and peptides useful therefor
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2155238B1 (en) 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
RU2582244C2 (ru) 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
KR101127476B1 (ko) * 2008-08-11 2012-03-23 아주대학교산학협력단 크링글 도메인의 구조에 기반한 단백질 골격 라이브러리 및 그 용도
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
JP5822822B2 (ja) * 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
KR20120093312A (ko) * 2009-10-30 2012-08-22 바이엘 헬스케어 엘엘씨 항체 모방체 스캐폴드
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
EP2496944A2 (en) 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
WO2011103583A2 (en) * 2010-02-22 2011-08-25 University Of Chicago Methods and compositions related to anti-angiogenic peptides
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
PT3498732T (pt) 2011-05-06 2022-02-02 Zoetis Services Llc Anticorpos anti-fator de crescimento do nervo e método para preparação e utilização dos mesmos
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
AU2012252152B2 (en) 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
SG10201500957QA (en) 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
US9447178B2 (en) 2011-06-28 2016-09-20 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
EA031181B1 (ru) 2011-06-28 2018-11-30 Оксфорд Байотерепьютикс Лтд. Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
EP3453400B1 (en) 2011-12-13 2021-01-20 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2013188578A1 (en) 2012-06-12 2013-12-19 The Johns Hopkins University Efficient, expansive, user-defined dna mutagenesis
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2881431C (en) * 2012-08-08 2021-10-19 Daiichi Sankyo Company, Limited Peptide library and use thereof
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3024847A1 (en) * 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) * 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) * 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US20190264197A1 (en) * 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
CN106220713B (zh) * 2016-08-08 2017-09-01 大连医科大学 一种蝎毒耐热合成肽及其用途
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
JP7225116B2 (ja) 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
US11583589B2 (en) 2017-08-23 2023-02-21 Cygenica Limited Cell membrane penetrating conjugates
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
RS64343B9 (sr) 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
WO2020039984A1 (ja) * 2018-08-20 2020-02-27 国立大学法人名古屋大学 化合物ライブラリ
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
AU2019408420B2 (en) * 2018-12-21 2025-04-17 Vib Vzw Fusion protein with a toxin and scaffold protein
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
GB201902648D0 (en) * 2019-02-27 2019-04-10 Cyca Oncosolutions Ltd Cell membrane penetrating conjugates
US20220154174A1 (en) 2019-03-08 2022-05-19 Oxford Genetics Limited Method of Selecting for Antibodies
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
US20230147657A1 (en) 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
EP3882257A1 (en) * 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Ngr conjugates and uses thereof
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
WO2022043686A1 (en) * 2020-08-25 2022-03-03 Thrombosis Research Institute Vaccine
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
AU2022253567A1 (en) 2021-04-08 2023-11-23 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
JP2025510588A (ja) 2022-03-11 2025-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞及びｔ細胞を特異的に初期化するための核酸系及びその使用
EP4584291A1 (en) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
PE20251544A1 (es) 2022-09-21 2025-06-05 Seagen Inc Nueva proteina de fusion especifica para cd137 y cd228
CN115851703B (zh) * 2023-01-04 2024-07-26 厦门大学 定向二硫键多元环肽库构建及配体筛选方法
WO2025085727A1 (en) * 2023-10-18 2025-04-24 Bandarian Vahe Papb as a bimoiety-dependent thioether installation tool
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
US20260092274A1 (en) * 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4284444A (en) * 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4200984A (en) * 1979-03-12 1980-05-06 Fink Ray D Detachable tool combining bracket and method
US4398908A (en) * 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) * 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
DE3581188D1 (de) * 1984-07-24 1991-02-07 Key Pharma Klebende schicht zur transdermalen freigabe.
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) * 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US6406713B1 (en) * 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4976696A (en) * 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5270176A (en) * 1987-11-20 1993-12-14 Hoechst Aktiengesellschaft Method for the selective cleavage of fusion proteins with lysostaphin
JP2717808B2 (ja) * 1988-08-10 1998-02-25 テルモ株式会社 シリンジポンプ
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5017378A (en) * 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5298022A (en) * 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
FR2647677B1 (fr) * 1989-05-31 1991-09-27 Roussel Uclaf Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5318540A (en) * 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) * 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5176502A (en) * 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US6517859B1 (en) * 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2113094T3 (es) * 1993-03-09 1998-04-16 Epic Therapeutics Inc Las microparticulas macromoleculares y metodos de obtencion.
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US20020042079A1 (en) * 1994-02-01 2002-04-11 Sanford M. Simon Methods and agents for measuring and controlling multidrug resistance
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016201A1 (en) * 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
AU725257B2 (en) * 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ATE314054T1 (de) * 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6395302B1 (en) * 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
ES2255155T3 (es) * 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US20050260605A1 (en) * 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US6329186B1 (en) * 1998-12-07 2001-12-11 Novozymes A/S Glucoamylases with N-terminal extensions
US6713086B2 (en) * 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US6183770B1 (en) * 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ATE449596T1 (de) * 2000-08-15 2009-12-15 Univ Illinois Verfahren zur herstellung von mikropartikeln
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
IN190699B (cg-RX-API-DMAC10.html) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
CA2445860A1 (en) * 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US6838093B2 (en) * 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
KR100407467B1 (ko) * 2001-07-12 2003-11-28 최수봉 리모컨 방식의 인슐린 자동주사기
CA2469477A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
MXPA06008126A (es) * 2004-01-14 2008-02-14 Univ Ohio Metodos para la produccion de peptidos/proteinas en plantas y peptidos/proteinas producidos de este modo.
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2006294644A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides

Similar Documents

Publication Publication Date Title
KR100484084B1 (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
KR101904385B1 (ko) 고안정성의 t 세포 수용체 및 이의 제조방법과 응용
WO2021104435A1 (zh) 一种生物磁性微球及其制备方法和应用
JP2023506765A5 (cg-RX-API-DMAC10.html)
JP2020516314A5 (cg-RX-API-DMAC10.html)
JP2024533311A5 (cg-RX-API-DMAC10.html)
JP2013534812A5 (cg-RX-API-DMAC10.html)
JP2010513506A5 (cg-RX-API-DMAC10.html)
RU2018117360A (ru) Сконструированные нуклеиновые кислоты, нацеленные на нуклеиновую кислоту
JP2010529860A5 (cg-RX-API-DMAC10.html)
JP2019506163A5 (cg-RX-API-DMAC10.html)
JPH10508470A (ja) 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
WO2021092075A1 (en) IL-2RβγC BINDING COMPOUNDS
JP2007289200A5 (cg-RX-API-DMAC10.html)
JP2012509900A5 (cg-RX-API-DMAC10.html)
JP2010531144A5 (cg-RX-API-DMAC10.html)
JP2015134758A5 (cg-RX-API-DMAC10.html)
JP2014526881A5 (cg-RX-API-DMAC10.html)
JP2012528191A5 (cg-RX-API-DMAC10.html)
JP2023538366A5 (cg-RX-API-DMAC10.html)
CA2457414A1 (en) Virus coat protein/receptor chimeras and methods of use
WO2012126157A1 (zh) 膜联蛋白v变体及其表达、制备和应用
JP2005523681A5 (cg-RX-API-DMAC10.html)
JP2013505287A5 (cg-RX-API-DMAC10.html)
JP2016508143A5 (cg-RX-API-DMAC10.html)